Melanoma Risk and Survival among Organ Transplant Recipients.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 26270022)

Published in J Invest Dermatol on August 13, 2015

Authors

Hilary A Robbins1, Christina A Clarke2, Sarah T Arron3, Zaria Tatalovich4, Amy R Kahn5, Brenda Y Hernandez6, Lisa Paddock7, Elizabeth L Yanik8, Charles F Lynch9, Bertram L Kasiske10, Jon Snyder11, Eric A Engels8

Author Affiliations

1: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. Electronic address: hilary.robbins@jhmi.edu.
2: Cancer Prevention Institute of California, Fremont, California, USA; Department of Health Research and Policy, Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, USA.
3: Department of Dermatology, University of California, San Francisco, San Francisco, California, USA.
4: Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
5: New York State Cancer Registry, Albany, New York, USA.
6: University of Hawaii Cancer Center, University of Hawaii, Honolulu, Hawaii, USA.
7: New Jersey State Cancer Registry, Trenton, New Jersey, USA; Rutgers School of Public Health, Piscataway, New Jersey, USA.
8: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
9: Department of Epidemiology, University of Iowa, Iowa City, Iowa, USA.
10: Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA.
11: Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA.

Articles cited by this

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06

Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93

Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ (1995) 3.30

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol (1999) 3.19

Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ (2005) 2.73

Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst (1986) 2.39

Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science (2005) 2.31

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22

Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90

Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst (1992) 1.79

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74

Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant (2008) 1.65

Ethnic differences among patients with cutaneous melanoma. Arch Intern Med (2006) 1.63

Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst (2015) 1.59

Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol (2014) 1.53

Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med (2003) 1.53

Skin cancer in organ transplant recipients--where do we stand today? Am J Transplant (2008) 1.35

Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol (2005) 1.35

Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol (2008) 1.33

Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA (1987) 1.30

Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28

Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ (2010) 1.18

Increased incidence of melanoma in renal transplantation recipients. Cancer (2005) 1.17

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer (2008) 1.16

Transmission of donor melanoma by organ transplantation. Lancet Oncol (2010) 1.15

The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol (1991) 1.12

Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol (2012) 1.10

Melanoma in immunosuppressed patients. Mayo Clin Proc (2012) 1.07

The objective assessment of lifetime cumulative ultraviolet exposure for determining melanoma risk. J Photochem Photobiol B (2006) 1.07

Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev (2009) 1.05

Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol (2002) 1.01

Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol (2011) 0.97

Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res (2014) 0.96

Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect (1993) 0.93

Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis. Cancer Prev Res (Phila) (2012) 0.92

De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91

Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol (1988) 0.91

Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) (2010) 0.87

Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol (1996) 0.84

Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol (1993) 0.83

Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. Am J Transplant (2014) 0.81